Viemed Healthcare, Inc. key statistics and ratios

In fiscal 2025, Viemed Healthcare, Inc. had return on equity of 10.9%, an operating margin of 8.5%, debt equal to 8.7% of equity and a current ratio of 1.18. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Viemed Healthcare, Inc.: financial ratios, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Gross margin	74.1%	69.8%	61.0%	62.7%	61.0%	61.6%	59.4%	57.5%	57.5%
Operating margin	15.6%	11.0%	20.4%	9.9%	5.9%	7.8%	8.0%	8.5%	7.5%
Net margin	14.7%	10.6%	24.0%	7.8%	4.5%	5.6%	5.0%	5.5%	4.8%
Free-cash-flow margin	25.2%	7.1%	16.8%	2.4%	3.5%	10.4%	0.6%	4.4%	9.7%
Return on equity	29.2%	22.4%	50.3%	10.3%	6.5%	9.7%	9.2%	10.9%	10.2%
Return on assets	17.7%	12.5%	32.3%	7.9%	5.3%	7.5%	6.8%	7.9%	7.2%
Asset turnover	1.20	1.18	1.35	1.02	1.18	1.35	1.35	1.44	1.50
Current ratio	1.18	1.07	2.05	2.66	2.11	1.19	1.42	1.18	1.13
Debt to equity	0.0%	21.5%	9.3%	6.1%	0.0%	6.2%	3.0%	8.7%	4.9%
Effective tax rate	1.7%	3.1%	−19.6%	27.0%	30.8%	28.8%	29.4%	29.4%	29.1%
R&D as % of revenue	0.0%	1.1%	0.8%	1.8%	1.9%	1.5%	1.4%	1.1%	0.8%
SG&A as % of revenue	53.2%	51.6%	40.2%	46.9%	49.1%	48.0%	47.4%	44.9%	45.1%
Capital spending as % of revenue	9.5%	16.7%	9.9%	16.9%	16.5%	14.3%	16.8%	14.8%	10.5%
Free cash flow ÷ net income	171.0%	66.9%	70.0%	30.1%	77.9%	186.7%	11.7%	79.9%	201.7%
Dividends and buybacks ÷ free cash flow	9.8%	26.7%	0.0%	0.0%	197.3%	0.0%	0.0%	110.8%	62.7%

US$ thousands unless shown otherwise. Fiscal quarters.

Viemed Healthcare, Inc.: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Gross margin	59.3%	59.5%	56.3%	58.3%	57.5%	57.9%	56.8%	57.7%
Operating margin	9.7%	10.6%	6.5%	8.1%	7.8%	11.0%	5.7%	5.7%
Net margin	6.7%	7.1%	4.4%	5.0%	4.9%	7.4%	3.4%	3.5%
Free-cash-flow margin	3.0%	5.2%	−21.4%	6.5%	14.9%	12.7%	1.8%	9.5%
Current ratio	1.31	1.42	1.38	1.48	1.13	1.18	1.22	1.13
Debt to equity	3.6%	3.0%	2.9%	3.1%	15.8%	8.7%	6.4%	4.9%
R&D as % of revenue	1.3%	1.3%	1.3%	1.3%	1.1%	0.8%	0.8%	0.6%
SG&A as % of revenue	46.0%	46.5%	48.1%	45.7%	44.4%	42.3%	46.1%	47.5%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

7 of 7 checks passed · June 30, 2026

What it owns · $204m

Short-term assets $54mLonger-term assets $150m

What it owes, and who funded it · $202m

Short-term liabilities $48mLonger-term liabilities $10mShareholders' equity $144m

Short-term assets cover short-term liabilities $54m of assets due within a year against $48m of liabilities due within a year.
Short-term assets cover long-term liabilities $54m short-term assets against $10m of longer-dated liabilities.
More cash than debt $11m of cash against $7m of debt.
Debt below 40% of shareholders' equity Debt is 5% of equity.
Debt burden no higher than five years ago Debt to equity moved from 5% to 5% over five years.
A year's operating cash flow covers at least 20% of debt $61m of operating cash flow against $7m of debt.
Operating profit covers interest at least five times over No material interest expense reported.

From Viemed Healthcare, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

62 /100

Moderate moat

How hard Viemed Healthcare's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 11 / 20

Net income has been a median 7.5% of total assets over 8 years.
Pricing power 17 / 20

Gross margin has been a median 61.2%, moving by 4.6 percentage points (standard deviation) across 8 years.
Durability 12 / 20

Operating margin has been a median 8.6%; its worst year was 6.3%.
Cash conversion 13 / 20

Free cash flow was positive in 7 of 8 years, at a median 7.5% of revenue.
Discipline 15 / 20

The diluted share count fell 1.0% over five years; stock-based pay has been a median 3.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (67 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: DCGO vs VMD DLHC vs VMD CDNA vs VMD

More: Health Care Services stocks compared, Health Care sector, rankings of US companies

Figures from Viemed Healthcare, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Viemed Healthcare, Inc.